Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis - Wikidata - wikimedia - TriplyDB

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis

http://www.wikidata.org/entity/Q38197613

about

A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD Management of non-alcoholic fatty liver disease in 2015 Endocrine causes of nonalcoholic fatty liver disease Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine Prevention of Hepatocellular Carcinoma Metformin and metabolic diseases: a focus on hepatic aspects Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.Delayed ethanol elimination and enhanced susceptibility to ethanol-induced hepatosteatosis after liver resection.Co-administration of metformin and N-acetylcysteine with dietary control improves the biochemical and histological manifestations in rats with non-alcoholic fatty liver.Keratin 18-deficiency results in steatohepatitis and liver tumors in old mice: A model of steatohepatitis-associated liver carcinogenesis.The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases.Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.Where does liver fat go? A possible molecular link between fatty liver and diabetes.Non-alcoholic Fatty Liver Disease: A Clinical Update.Comparison of Pioglitazone and Metformin Efficacy against Glucocorticoid Induced Atherosclerosis and Hepatic Steatosis in Insulin Resistant Rats.Co-administration effects of aqueous extract of turnip leaf and metformin in diabetic rats.Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety.Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model.Obesity and nonalcoholic fatty liver disease: current perspectives Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis

P2860

Q26752487-823762E4-1093-4D00-A0FC-1FE3DE4CF8AC Q26771148-6B474D46-B312-4AF5-9A87-D71AA06B235A Q26780254-C3FF793F-238F-4DD5-85E3-4DBA5EF020AA Q26992163-89B25865-58F8-45CD-86B7-6A18DEF3375E Q28079576-91F5FE5E-0639-413E-932A-D260C482433C Q28082736-0AF58429-1FDB-4B34-B8E8-D1EFB5837695 Q30396916-DAE135F2-0B44-4569-A47E-2BB8E73E2198 Q34779140-CF0AAB1F-0094-46FC-8BB5-8B7E42888C67 Q37438847-AD97C036-15F3-49D8-B515-F429D8BB8B89 Q37687384-F70BAE03-DD98-4339-A639-D79CA4EF611B Q38676257-6B8E2E89-ACE6-4A51-8985-35BE21610F05 Q38867031-3D9B7BA3-C54D-4C85-89DF-1D2EC016334E Q42318779-CE5AC879-2B4F-4E59-94A9-68F8DD0FF7B0 Q47100244-B350E3B3-0D6F-458E-8CBE-68FCFB6CF9A0 Q48002814-5190BCBA-58B9-4436-8B84-78D39B5ACB45 Q49199230-593E95CE-3B97-429F-80AF-0E2B1951DED1 Q49356193-8E2E6E7D-122D-4DD5-AA32-1D621DC63755 Q52590946-B999029A-BC70-4AFA-BA9D-7D2812FF3D5D Q55434689-D9413F00-4AF6-488F-A241-EAAD8623B143 Q57069715-2CEC97DC-7FF6-4F8F-B46C-51E8C7C4AA70 Q57494353-C17608FD-48CE-450F-B78C-7D1E14942221 Q58588579-3FD3692F-EFB7-4083-886F-6BD0676DE2BD

P2860

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis

http://www.wikidata.org/entity/Q38197613

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis

@en

type

label

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis

@en

prefLabel

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis

@en

P1433

Q38197613-21E6CF52-182E-41AD-8DEB-299099B0F67D

P1476

Q38197613-34CD1F6A-01AE-4EA6-9AE6-B1106257F8FD

P2093

Q38197613-3FC0940B-5A7F-4E0B-AAE7-370CBC99672E

Q38197613-47C0B9ED-2CFE-4216-AB31-1FC7D7A491C9

Q38197613-82501D34-6E3D-4DEA-87BA-D43CE6A4AD4C

Q38197613-F35B436B-BF45-468C-A28C-15D01DD7D94F

Q38197613-F35F2F2E-8B91-4565-BA95-B606E187E095

P2860

Q38197613-07DF28FB-80FB-4143-A179-D3DDA8561BD0

Q38197613-10218E4F-F900-40C4-970F-131472AF7D50

Q38197613-1A2F8A6E-6DAC-4834-89DA-C3F903F23970

Q38197613-1DFF640E-F6BE-47A7-B3A7-4CB761CC9FA0

Q38197613-21019744-E538-45FF-96C8-CBEE8DEEF28B

Q38197613-23D0A336-2B43-4294-8FF6-7BF338D7C4BA

Q38197613-3397C681-E610-49EF-8329-A7093BE85296

Q38197613-34E41A88-B01A-4C18-9054-F0CBAEF5C62B

Q38197613-3B1337C4-A5FE-48DA-8788-FBD31385E660

Q38197613-5502D442-9BF3-4279-9D03-49CA37C7ADE8

P304

Q38197613-BED669F8-E709-402D-9FAA-4A46672A0BCB

P31

Q38197613-AA7D6747-6348-4CFE-BD28-B3B18FADD402

P356

Q38197613-B7E9826A-5948-4763-8F27-A8DF2BB06DAF

P433

Q38197613-CAFA8201-C64F-4389-BEC1-8601B58BDE9E

P478

Q38197613-9E8B4D28-F5CB-4EE1-A711-FA2853509A96

P577

Q38197613-6F1411E9-ACE5-4536-8FC8-7AED14050345

P698

Q38197613-E262EC73-3ADA-4EA2-9889-52F564286083

P921

Q38197613-38BFA5CD-D8C0-40C6-A833-05F9C27680CE

P932

Q38197613-FC71ACC9-112A-40D3-A564-52AE3735FCC9

P356

P1433

Biomedical Reports

P1476

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis

@en

P2093

Bin Wang

http://www.w3.org/2001/XMLSchema#string

Dongfeng Chen

http://www.w3.org/2001/XMLSchema#string

Jun Wang

http://www.w3.org/2001/XMLSchema#string

Lei Liu

http://www.w3.org/2001/XMLSchema#string

Yan Li

http://www.w3.org/2001/XMLSchema#string

P2860

Role of AMP-activated protein kinase in mechanism of metformin action

Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis

Treatment of non-alcoholic fatty liver disease

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

The metabolic syndrome--a new worldwide definition

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

Molecular mediators of hepatic steatosis and liver injury

Nonalcoholic fatty liver disease

Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.

Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.

P304

57-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/BR.2012.18

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24648894

http://www.w3.org/2001/XMLSchema#string

P921

P932

3956897

http://www.w3.org/2001/XMLSchema#string